Problems with registration of cutaneous malignant melanoma in England. by Melia, J. et al.
British Joumnal o Cancer (195) 72 224-228 x © 1995 Stockton Press All nghts reseved 0007-0920/95 $12.00
Problems with registration of cutaneous malignant melanoma in England
J Melia', T Frost2, R Graham-Brown3, J Hunter4, A Marsden5, A du VivierP, AP Warin2,
J White7, S Whitehead8, M Wroughton9, R Eliman' and J Chamberlain'
'Cancer Screening Evaluation Unit, Institute of Cancer Research, Section ofEpidemiology, D Block, Cotswold Road, Sutton,
Surrey SM2 5NG; 2Department ofDermatology, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DE; 3Department
ofDermatology, Leicester Royal Infirmary, Infirmary Square, Leicester LE] 5WW; 4Department ofDermatology, Level 4, Phase
1, The Royal Infirmary, Edinburgh EH3 9YW; 5Department ofDermatology, St. George's Hospital, Blackshaw Road, London
SWJ7 OQT; 6Department ofDermatology, King's College Hospital, Denmark Hill, London SE5 9RS; 7Royal South Hants
Hospital, Graham Road, Southampton, Hants S09 4PE; 8Department ofPublic Health Medicine, South Derbyshire HA, Boden
House, Main Centre, Derby DEl 2PH; 9Department ofDermatology, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Summary The aim of the study was to assess the completeness and accuracy of cancer registration for
cutaneous malignant melanoma. The study was conducted in seven health districts in England and one health
board in Scotland from 1987 to 1989 with a total resident population of 3.6 million. Records from pigmented
lesion clinics and pathology laboratories colected during the Cancer Research Campaign's health education
programme to promote the early detection of melanoma were matched with cancer registrations from a total
of five regional cancer registries. In England 74% out of a total of 642 cases of invasive malignant melanomas
(ICD 172) and 44% out of a total of 155 in situ melanomas (ICD 232) had been registered compared with
96% and 100% respectively in Scotland. A significantly higher proportion of late-stage cases was found among
registered than among non-registered cases in England (P<0.001). In all registries the majority of superficial
spreading in situ melanomas were miscoded as invasive cases. The annual incidence of invasive malignant
melanoma in tie English study areas was found to be seven per 100 000 in men and 11 per 100 000 in women,
similar to that reported in Scotland. The registries are best at recording thick or late-stage melanomas. As the
skin cancer target for Health of the Nation depends on monitoring trends in the incidence of malignant
melanoma, future improved ascertainment of cases and changes in the type of cases being registered must be
taken into account.
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In the government White Paper 'Health of the Nation' a
target for skin cancer has been set 'to halt the year-on-year
increase in the incidence of skin cancer by 2005' (Department
of Health, 1992a). Monitoring trends in the incidence of
non-melanocytic skin cancers (International Classification of
Diseases, 9th revision: ICD9) is known to be problematic
because of incomplete registration (Roberts, 1992). In 1993
some English registries ceased registration of basal cell car-
cinomas.
Although there has undoubtedly been a true increase in the
incidence of malignant melanoma (ICD9 172) in England in
recent decades, some of the steep rise is likely to be explained
by improved ascertainment of cases for registration. Of 20
cases of melanoma occurring from 1968 to 1985 in an Eng-
lish population of 17000 women aged 25-49 years, eight
(40%) had not been registered (Villard-Mackintosh et al.,
1988). More recently the Thames Cancer Registry (1994)
estimated that 28-31% of malignant melanomas had not
been registered, using a calculation based on the distribution
of survival, cause of death and chance of being registered
from medical records. In contrast, Scotland is believed to
have nearly complete registration because of the Scottish
Melanoma Group register established in 1979 (MacKie et al.,
1992); this register, set up by dermatologists, surgeons and
pathologists, exchanges information every year with the Scot-
tish Cancer Registries. The higher incidence rates reported in
Scotland (7.1 per 100000 and 10.4 per 100000 in males and
females respectively) than in England (3.9 per 100000 and
6.1 per 100000 in males and females respectively) (Melia et
al., 1994a) for 1986-88 standardised by age to the 1987
England and Wales population may in part have occurred
because of more complete registration in Scotland.
A study had been set up in England and Scotland to
evaluate the long-term effects of a health education pro-
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gramme for the early detection of melanoma (Eliman, 1991).
The opportunity was taken to use the data to investigate the
extent of under-registration of malignant melanoma, biases
arising in the type of cases being registered and errors in
diagnostic coding. The Cancer Research Campaign (CRC)
funded a health education programme from 1987 to 1989 in
seven English health districts and one Scottish health board.
To study the impact of the programme on the incidence of
malignant melanoma, data were collected from pigmented
lesion clinics, pathology laboratories and cancer registries.
The data from these sources have been compared to inves-
tigate the registration of melanoma.
Metbods
Data collection
The aim of the health education programme was to promote
the early detection of melanoma in the general public. Seven
distnrct health authorities in England (Camberwell, Exeter,
Leicester, Nottingham, Southampton and South-West Hamp-
shire, and Wandsworth, Merton and Sutton combined) and
Edinburgh City within Lothian Health Board were selected
because local melanoma registries were already being run by
the dermatology clinics. The areas yielded a target popula-
tion of 3.6 million from a range of rural and urban areas.
The CRC funded pigmented lesion clinics (PLCs) in each
area to cope with the extra workload expected after the
launch of the programme on 8 July 1987. A standardised
form was used at the PLCs to coUlect data on the demo-
graphic and clinical details of each patient. The programme,
which promoted its message through the local media and
leaflets and posters, was most active during the summer of
1987, but additional publicity was promoted in some study
areas in 1988 and 1989. The PLCs were funded until the end
of 1989.
The main aim of the evaluation study is to investigate theeffect of the campaign on mortality from melanoma. To
establish a database for this invesugation, information on
melanoma cases was collected from four main sources: the
PLCs, local melanoma registers based on patients attending
dermatology departments in hospital rather than population
based; the main histopathology laboratories serving the study
areas; and regional cancer registries. It was inpractcal in this
study to contact all histopathology laboratories which might
have diagnosed patients treated outside but resident in the
study areas, especially in the Tbames regions, where there is
consideable cross-boundary flow for treatment Although
most laboratories have computerised databases, many did
not record an address, which is essential to identify people
according to area of residence, and many could not down-
load information on diskc. As a result the histopathological
data which were used in the study had to be extracted
manually.
Defintion ofcases
In this paper completeness of registration is estimated from
the proportion of registered cases among all cases of invasive
malignant melanoma and in situ melanoma of the skin, first
diagnosd during the campaign period 8 July 1987 to 31
December 1989. Malignant melanomas of the eye and
urogenital area have been excluded. A case is defined as a
person counted at the time of the first melanoma being
diagnosed. Synchronous melanomas are counted as one case
and subsequent cases or recrrence have not been included
in the analyses.
Cases of invasive malignant melanoma recorded by PLCs,
pathology laboratories and local hospital-based registers
included superficial spreading, lentigo maligna melanomas,
acral, nodular and non-specified types of malignant mela-
noma. In situ melanomas included cases of superfical
spreading melanoma in situ, lentigo maligna and non-
specified types of malignant melanoma recorded as in situ or
with a Breslow thickness of zero. All cases from these sources
were pathologially confirmed. From the cancer registes,
cases diagnosed during the study period which were
registered by March 1994 were included. The proportion of
regstered melanomas recorded as pathologcally confirmed
ranged from 89% at one English registry to 99% in Scotland.
Invasive malignant melanoma is coded as ICD 172 with a
behaviour code ending with 3 using the 9th revison of the
International Classfication of Diseass (ICD9), or alterna-
tively as ICD 173 with behaviour code ending with a 3 and
morphology within the range 872-879 when using the
specialty-based adaptation of the 9th revision for oncology
(ICDO). In situ melanomas should be coded as ICD 172 and
behaviour code ending with 2 when using the 9th revision or
as ICD 173 and behaviour code ending with 2 when using
ICDO. The data collected from other sources in the CRC
study also used Breslow thickness to help define invasive and
in situ lesions, lesions with a Breslow thickness of zero or not
applicable being coded as in situ. This may not always hap-
pen for cases collec by the registres, and some may
depend solely on whether or not the term in situ is clearly
specified in the patient's notes.
Where registered cases were matched to the cases identified
from other sources, and dicrepani found, the clinical and
pathology records were checked to confirm the correct diag-
nosis. These showed that the data from other sources were
correct for 99% of cases and therefore, in the analyses of
registration rates and characteristics of registered cases,
priority was given to the diagnosis recorded from other
sources, not the cancer registries. For cases recorded only by
the registry, it was not feasible to check the pathology
records because of the large number of laboratories involved,
so the diagnosis recorded by the registry was assumed to be
correct in the analyses.
Analysis
By matching cases identified from other sources with those
on the cancer register, the proportions of invasive malignant
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melanoma and in situ melanomas which had been correctly
regstered were found. If data on Breslow thickness were
missing, cases with metastases or recorded as late stage at
time of diagnosis were classified in a group which included
cases where Breslow thickness was >3.0 mm. For registered
cases a comparison of the diagnosis as recorded in hospital
case notes and by the cancer registries was made. The
analyses were conducted using simple tabulations and the
chi-squared test to test for significant differences between
groups. Multifactorial regression analyses were conducted to
study the relationship between registration and age, sex and
Breslow thickness using the SPSS computer package.
Result
A total of 787 invasive malignant melanomas and 179 in situ
melanomas were diagnosed in the study areas during the
study period. For the invasive malignant melanomas, a
significantly lower proportion of cases diagnosed in England
were registered (74%) than among cases diagnosed in Scot-
land (96%) (P<0.001). In the four English registies the
ascertaiment rate ranged from 66% to 88% (Table I).
Analysis of invasive malignant melanoma by source showed
that overall 173 (22%) cases were identified by the registries
alone, 172 (22%) cases by other sources alone and 442 (56%)
cases by both. The proportion of cases identified by the
registry alone was highest in London (37%), where there is
cross-boundary flow of treatment and cases had been treated
elsewhere.
In situ melanomas were substantially under-registered in
the English areas (44%, range 23-58%) compared with
100% registration in Scotland (Table I). Nimeteen (10%)
cases in England and Scotland (all lentigo malignae) were
found on the registries alone, 87 (49%) by other sources
alone and 73 (41%) by both.
In England, the percentage ofinvasive cases registered was
higher for thick melanomas (>3.1 mm) than thin melanomas
(<1.5 mm) (Table H, P<0.001). The distribution of non-
registered and registered cases also differed by age, there
being higher proportions of non-registred cases in the
younger than other age groups (P<0.01). However, age was
related to the distribution of Breslow thickness, with younger
age groups having significantly thinner Breslow thicknesses.
There was no significnt variation in registration according
to sex. In multifactorial regression analyses to study the
relation between registration, age, sex and Breslow thickness,
Breslow thickness was the only variable signintly related
to registration (P<0.01).
In Edinburgh only six cases of invasive malignant
melanoma had not been regitered. Two had the diagnosis
misclassified in the registry, one person had a dual address in
Edinburgh and London and three had not been reported by
the registry.
Looking only at cases recorded by both the registries and
other sources, the diagnosis recorded from hospital records
was compared with the cancer registry codings. For the 442
cases recorded as invasive malignant melanoma by other
sources, there was 99% agreement in the diagnoses between
the registries and other sources. For the 73 cases recorded as
in situ melanoma by the other sources, there was a consistent
discrepancy across all registries in England and Scotland
Lentigo malign was correctly coded by the registries as in
situ meanoma for 25 out of 27 cases. However, 33 out of 37
cas of in situ superficial spreading melaa and a further
nine cases of unspecified melanoma in situ were recorded as
invasive malignant melanoma by the rgistries.
Taking all cases ofinvasive malignant melanoma identified
from all sources, the annual incdence rate of meanoma is
estimated to be seven and 11 per 100000 in males and
females respectively in the English study areas and nine and
15 per 100000 resectively in Edinburgh, age sandardised to
the population of England and Wales in 1988. Taking
registered ca only, the incdence rate of maligant
melanoma in the study areas is very similar to that reportedPobuws d - m gismam o i
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Table I Percentage (number in brackets) ofinvasive malignant melanomas and in situ melanomas diagnosed between 1987 and 1989 according to
data soureb
England Scotland
Camberwell, Southampton
Merton, Sutton Leicester and and S.W. Edinburgh
Study area Exeter and Wandsworth Nottingham Hampshire Total City Total
Region of registry South Western Thames Trent Wessex Scotland
Invasive malignant melaoma
ICD9 172
Total number of cases 100 (108) 100 (139) 100 (263) 100 (132) 100 (642) 100 (145) 100 (787)
ascertaied from all sources
Per cent registry only' 13 (14) 37 (52) 12 (32) 30 (40) 21 (138) 24 (35) 22 (173)
Per cent both registry and non- 53 (57) 31 (42) 62 (162) 58 (77) 53 (338) 72 (104) 56 (442)
registry sourcese
Per cent other sources only 34 (37) 32 (45) 26 (69) 12 (15) 26 (166) 4 (6) 22 (172)
In situ melanma
ICD9 232
Total number ofcases 100 (44) 100 (21) 100 (78) 100 (27) 100 (155) 100 (24) 100 (179)
asertained from all sources
Per cent registry onlya 2 (1) - 9 (7) 2 (17) 6 (10) 37 (9) 10 (19)
Per cent both registry and non- 21 (9) 48 (10) 44 (34) 41 (5) 38 (58) 63 (15) 41 (73)
registry sources
Per cent other sources only 77 (34) 52 (11) 47 (37) 42 (5) 56 (87) - 49 (87)
'Registered by March 1994. bpAB cases pathologically confirmed except a small proportion ofcases identified by the registries alone as explained in
Methods.
Table k The percentage (number given in brackets) ofregistered and non-registered cases of
invasive malignant melanoma in the English study areas according the Breslow thickness
Breslow thickness (mm) Breslow thickness
S 1.5 1.51-3.0 >3 lb Total not known
Registered 65.7 (199) 67.5 (77) 84.8 (95) 70.1 (371) 105
cases
Non-registered 34.3 (104) 32.5 (37) 15.2 (17) 29.9 (158) 8
cases
Total 100 (303) 100 (114) 100 (112) 100 (529) 113
ax2 with two d.f. = 14.8 for difference in registration by Breslow thickness (P<0.001).
bIncludes gstered cases with no data on Breslow thickness but recorded with late stage or
metastases.
by the cancer registries for the whole of England (six and
nine per 100000 in males and females respectively) and the
whole of Scotland (nine and 12 per 100000 for males and
females respectively).
Dicossio.
The under-registration of malignant melanoma identified in
this study has implications for the Health of the Nation
target for skin cancer (Department of Health, 1992a). It has
been proposed in the Specifiction of National Indicators for
the Health of the Nation (Department of Health, 1992b)
that incidence should be monitored separately for both
non-melanocytic skin cancers (ICD9 173) and malignant
melanoma (ICD9 172). Both clearly suffer from under-
registration, and incidence rates can be expected to show an
apparent increase in the next few years if ascertainment by
the cancer registries improves and if there is increased diag-
nosis of early-stage, sometimes non-progressive, disease. The
cancer registries seem best at recording late-stage malignant
melanomas, and therefore ideally the incidence rate of malig-
nant melanoma should be monitored by stage using an index
such as Breslow thickness. Breslow thickness has a strong
association with prognosis with only 25% of patients with
tumours thicker than 3.0mm surviving 5 years compared
with 91% of patients with tumours less than 1.51 mm (Bres-
low, 1970).
Under-registration of invasive malignant melanoma was
low in this study (25%) compared with the 40% reported by
Villard-Mackintosh et al. (1988). Comparisons between the
two studies must be made with caution because ascertain-
ment of cases will vary between registries and over time, and
also the present study had a much larger population. This
study reports on melanomas diagnosed from 1987 to 1989 for
the total population in areas covered by four English regist-
ries, whereas the other study focused on women aged 25-49
years reporting melanomas from 1968 to 1985. An alternative
comparison with the Thames Cancer Registry's own estimate
ofunder-ascertainment for malignant melanoma showed very
similar results to those in the CRC study (Thames Cancer
Registry, 1994). Variation in under-registration between
registries in part reflects the different methods of data collec-
tion used by the registries. Among the English registries
registration was highest for the area covered by the Wessex
registry, which has established good links with pathology
laboratories for several years.
There are two limitations with the data set which may
have led to underestimates of the extent of under-
ascertainment. First, it is possible that ascertainment was
more complete in the CRC study areas than elsewhere
because local dermatological melanoma registers, activities of
the health education programme and associated research may
have encouraged exchange of information between the hos-
pitals and cancer registries. Second, as it was impractical to
collect data from all pathology laboratories diagnosing cases
treated outside the study areas, some melanomas may have
remained undetected, particularly in areas where pathology
links with registries were poor. Thus the ascertainment rate
overall in England may be lower than that estimated in thisPr m-md o
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study. On the other hand, the prsence of local registers and
research can sometimes hinder cancer registration if, for
example, patients' notes are removed for these purposes and
thus cannot be foun in the routine searches by registry staff.
Under-ascertaiment is bound to vary between registres
across England, and the four English registries may not be
representative of all registries. However, the registies had a
mix of data collection methods similar to those used
elsewhere. Further analysis of the data with respect to stage
and patient characteristics (Melia et al., 1995) has shown
similarities between the full data set for the study areas and
that for the whole of Scotland (MacKie et al., 1992) where
there is near complete registration suggestng that there is no
substantial bias in the data set presented here.
The under-registration of cancers in England and Wales
and various reasons for this are well recognised (Bean et al.,
1982; Silcocks et al., 1989). The important issues arising from
the present study are firsty the biases in types of melanomas
being registered, which will affect the interpretation of trends
in incidence, and secondly errors in the diagnostic coding of
in situ cases.
The main bias is the incomplete registration of thin malig-
nant melanomas. As awareness about melanoma increases in
the gneral public in Brtain, the number of thin malignant
melanomas at diagnosis will also increase (MacKie et al.,
1992; Melia et al., 1994b). Most cases of thin malignant
melanoma are treated on an out-patient basis with simple
excision, require no further treatment and rarely lead to
death. Therefore under-registration ofthese cases will be high
in registries which depend largely on data from in-patient
discharge records, radiotherapy departments and death
certificates. Therefore pathology laboratories are a very
umportant source.
Both the under-registration and bias in type of cases being
registered could lead to misinterpretation of geographical
variation in incidence rates for malignant melanoma both
within the UK and abroad. Asertainment of melanoma
cases by registries is believed to be high in areas of Australia
where pathology records are used as a source of information
(Bonett et al., 1989). There has certainly been an increase in
the incidence of malignant melanoma in Australia, but some
of the rise in parts of Australia may be explained by
improved ascertainment (Jones et al., 1992). In contrast, in
one state in USA the under-registration of melanoma cases
increased from 2% in 1974 to 21% in 1984 (Karagas et al.,
1991), probably because ofincreased diagnosis ofthin lesions
which were not being picked up by the registries.
The problem with the coding of in situ superficial
spreading melanomas as invasive may have occurred because
of lack of understanding of the use of the matrix system for
the coding of such lesions in ICD9 and ICDO. Some con-
fusion may also have been caused by a variety of terms used
in clnical records. Thus, in situ supfiial spreading
melanomas may not have been recognised as such if the term
'malignant' was used or if 'in situ' was not clearly specified.
Although it will have led to an over-reporting of invasive
malignant melanoma, the numbers are too small to have a
major impact on estimates of incidence. It is possible that
with increased reporting of thin melanomas this could
become a sizeable problem. It has also been reported in
Australia as a source of error (English et al., 1986), and a
similar coding error has been reported for cervical cancer
(Choyce and McAvoy, 1990). Special studies would help to
clarify the extent of this problem for other cancer sites.
In England ascertainment of many cancers will improve as
the registries develop linis with pathology laboratories (Cod-
ling et al., 1990). The registries should also be encouraged to
record prognostic indice for melanoma as trends in
melanomas with a poor prognosis will precede changes in
mortality and they are an important marker for improve-
ments in early detection of the disease. Breslow thickness is
one of the most reliable measures of prognosis, although
there are some probklms with its accuracy (Colloby et al.,
1991). The vertical growth component, which is positively
correlated with Breslow thickness, may be a better indicator
of prognosis as it requires assessment of two additional
components: cytology of the cells and more importantly, the
level of invasion of the dermal microenvironment (Clark et
al., 1989). Completeness of these data will depend on both
the pathologists and registry staff. The proportion ofinvasive
malignant melanomas for which Breslow depth is routinely
measured in England is not known. The completeness of
these data (95%) at the pathology laboratories in this study
may be higher than that occurring elsewhere if there is no
special interest in melanoma. The complteness of data
recorded by registry staffdoes need to be improved as at one
registry in this study only 7% of Breslow thicknesses given in
the hospital notes had been recorded by the registry.
The main factor affecting the interpretation of trends in
incidence of malignant melanoma in England is the underes-
timate of incidence in young adults and those with thin
tumours. As ascertainment continues to improve, some of the
apparent increase in incidence seen in the future will reflect
this improvement. Incidence rates for malignant melanoma
should ideally be monitored by Breslow thickness or stage as
registries have been best at recording late-stage cancers and
most improvement in ascertaiment is expected for early-
stage thin cancers. Inrsed collaboration between path-
ology laboratories, dermatologists and cancer registries will
help to resolve problems with registering melanoma and
increasing the recording of data on Breslow thickness.
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